# High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)

> **NCT01313507** · PHASE3 · COMPLETED · sponsor: **Octapharma** · enrollment: 21 (actual)

## Conditions studied

- Primary Immunodeficiency Disease

## Interventions

- **BIOLOGICAL:** NewGam

## Key facts

- **NCT ID:** NCT01313507
- **Lead sponsor:** Octapharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2017-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01313507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01313507, "High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01313507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*